Hepatitis B virus (HBV) is the major cause of acute and chronic hepatitis which could lead to hepatocellular carcinoma. Currently, interferon- α and nucleosidic inhibitors of HBV reverse transcriptase, polymerase, lamivudine (3TC), adefovir and entecavir are the only drugs approved for the treatment of chronic HBV infection. However, interferon-α-produces many side affects with partial efficacy less than 30% of the chronic carriers responding to treatment. In addition, about 50% of the patients who respond positively to interferon- α treatments are known to suffer recurrence of...